^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + IO102-IO103 (PD-L1 inhibitor, IDO inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1038P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)
Published date:
10/16/2023
Excerpt:
...NSCLC, with PD-L1 tumor proportion Score ≥50% (Cohort A); recurrent or metastatic SCCHN with PD-L1 combined positive scores ≥20 (Cohort B)….Cohort A, 8 pts (53.3%) had a partial response (PR; 4 confirmed), while 5 had stable disease; 2 pts had progressive disease (PD). In Cohort B, 2 pts (50%) had a PR (1 confirmed) and 2 pts had PD....This preliminary analysis suggests combining IO102-IO103 and pembrolizumab in pts with metastatic NSCLC and recurrent/metastatic SCCHN is tolerable, with encouraging clinical activity, and supports further development.
Trial ID:
